MannKind shares slipped despite the FDA expanding Furoscix use to certain pediatric patients, as investors questioned the approval limited near-term commercial impact. The company also secured five new US patents for its ReadyFlow autoinjector, which remains under FDA review, with a decision expected by July 2026.